Inclusion Criteria:

1. * ≥18 years old
2. * Locally-advanced or metastatic solid tumor with KRAS G12D mutation
3. * Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment to improve the disease outcome
4. * Cohort specific requirements as follows:

1. * Part 1A: Histologically or cytologically confirmed malignant solid tumor of any tissue origin
2. * Part 1B

1. * Disease group 1: diagnosis of PDAC
2. * Disease group 2: diagnosis of CRC
3. * Disease group 3: diagnosis of NSCLC
4. * Disease group 4: diagnosis of other advanced solid tumor and not part of Disease groups 1, 2 and 3
5. * Parts 2A and 2B

1. * Combination 1: Diagnosis of CRC or CRC
2. * Combination 2: Diagnoses of PDAC, CRC or NSCLC
3. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

1. * Prior treatment with any KRAS G12D inhibitor
2. * Known additional invasive malignancy within 1 year of the first dose of study drug
3. * History of organ transplant, including allogeneic stem cell transplantation
4. * Significant, uncontrolled medical condition
5. * History or presence of an ECG abnormality
6. * Inadequate organ function

Other protocol-defined Inclusion/Exclusion Criteria may apply